Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
An adenosine analog that acts as a highly selective agonist of adenosine A3 receptor (Ki = 330 pM, 820 nM, 470 nM for A3, A1 and A2A, respectively). Shown to reduce ischemia reperfusion injury in mice and limit infarct size in isolated rat hearts. Shown to reversibly increase field excitatory postsynaptic potentials in hippocampal slices and exhibits excitatory effects on both evoked and spontaneous epileptiform discharges.
A highly selective agonist of adenosine A3 receptor (Ki = 330 pM)
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Nucleosides, nucleotides, and analogues |
| Classe | Purine nucleosides |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Purine nucleosides |
| Alternative Parents | Glycosylamines 6-alkylaminopurines Benzylamines Secondary alkylarylamines Aminopyrimidines and derivatives Iodobenzenes 2-halopyrimidines Aryl iodides Aryl chlorides Imidolactams N-substituted imidazoles Tetrahydrofurans Heteroaromatic compounds Secondary alcohols Secondary carboxylic acid amides Amino acids and derivatives 1,2-diols Oxacyclic compounds Azacyclic compounds Carbonyl compounds Hydrocarbon derivatives Organic oxides Organochlorides Organoiodides Organopnictogen compounds |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Purine nucleoside - Glycosyl compound - N-glycosyl compound - 6-alkylaminopurine - 6-aminopurine - Imidazopyrimidine - Purine - Benzylamine - Aminopyrimidine - Halobenzene - Halopyrimidine - 2-halopyrimidine - Iodobenzene - Secondary aliphatic/aromatic amine - Aryl chloride - Aryl halide - Aryl iodide - Monocyclic benzene moiety - Imidolactam - Benzenoid - N-substituted imidazole - Pyrimidine - Tetrahydrofuran - Azole - Heteroaromatic compound - Imidazole - Secondary carboxylic acid amide - Secondary alcohol - 1,2-diol - Carboxamide group - Amino acid or derivatives - Secondary amine - Oxacycle - Azacycle - Carboxylic acid derivative - Organoheterocyclic compound - Carbonyl group - Amine - Organohalogen compound - Alcohol - Organic nitrogen compound - Organooxygen compound - Organic oxide - Hydrocarbon derivative - Organoiodide - Organochloride - Organic oxygen compound - Organopnictogen compound - Organonitrogen compound - Aromatic heteropolycyclic compound |
| Descrizione | This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. |
| External Descriptors | Not available |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Data | Oggetto |
|---|---|---|---|
| Certificate of Analysis | Nov 20, 2025 | C133243 | |
| Certificate of Analysis | Oct 28, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 | |
| Certificate of Analysis | Aug 11, 2025 | C133243 |
| Solubilità | Solvent:DMSO, Max Conc. mg/mL: None, Max Conc. mM: 100 |
|---|---|
| Sensibilità | light & heat sensitive |
| Punto di fusione (°C) | 207.0 to 211.0 °C |
| Peso molecolare | 544.700 g/mol |
| XLogP3 | 1.900 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 544.012 Da |
| Monoisotopic Mass | 544.012 Da |
| Topological Polar Surface Area | 134.000 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 623.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
Item-specific, validated protocols are not provided in the Product Data. The following are general, literature-based guidelines for using adenosine A3 receptor agonists in research. Adjust to your system and consult the SDS/CoA.
Stock preparation:
Cell-based agonism assay (general outline):
Membrane binding (radioligand displacement; general):
Analytical standard preparation:
All procedures are for research use only.
Functional class (literature): Potent, selective agonist of the adenosine A3 receptor (A3AR), a Gi/o‑coupled GPCR. The “2‑Cl‑IB‑MECA” scaffold incorporates modifications (2‑chloro on purine, 3‑iodobenzyl at N6, and 5′‑N‑methyluronamide) known to enhance A3AR affinity and selectivity relative to A1/A2A subtypes.
Mechanistic notes (general, not item-specific claims):
Typical research uses:
Selectivity considerations (literature):
Note: All uses are for research only. No medical or clinical claims are made.
This compound is not a buffering agent. However, it is commonly prepared and used in biological buffers for receptor assays.
Practical guidance (general, not item-specific specs):
Filtration: 0.22 μm filtration of working solutions can remove particulates; pre-wet filters with buffer containing the same DMSO percentage to minimize adsorption.
Compatibility: Avoid strong acids/bases that can degrade nucleosides; maintain neutral pH to preserve integrity during experiments.
For this bioactive ligand, the main environmental consideration is solvent choice for solution preparation and analytical work rather than replacing the molecule itself.
Greener solvent strategies (general guidance):
Comparison (general, not item-specific specs):
Operational improvements:
No therapeutic or clinical use is claimed for this catalog item. The following describes research/formulation roles only.
Research/formulation roles (general):
Pharmacopeial status: Not specified for this item; refer to CoA/Spec Sheet.
Excipients/compatibility (general considerations):
Note: For any regulated application, qualification of identity, purity, and stability must be established with your internal procedures and the specific CoA for the lot in use.
Item-specific values: Not specified for this item; refer to CoA/Spec Sheet.
Practical appearance/phase (item-specific): Not specified for this item; refer to CoA/Spec Sheet.
Solubility guidance (general/literature, not a specification):
Other literature properties (indicative only, not item-specific specs):
Refractive index, pKa, melting point, density, UV–Vis: Not specified for this item; refer to CoA/Spec Sheet. If needed for method development, consult primary literature for 2‑Cl‑IB‑MECA or request the Aladdin CoA.
Grade: Moligand™
What this means for this item:
Stabilizers/format: Not specified for this item; refer to CoA/Spec Sheet. No stabilizer is implied unless stated.
Use-case suitability (general guidance):
This compound is primarily a bioactive research ligand rather than a synthetic reagent. Accordingly, its most relevant “applications” are biochemical/analytical rather than chemical transformations.
Biochemical/analytical applications (literature guidance):
Not typically used for synthetic reactions. If derivatization is required (probe development), typical transformations target:
Practical handling tips:
This product is not typically used to drive chemical reactions; therefore, there are no standardized “reaction conditions” specific to it. For researchers intending to derivatize it (probe synthesis), the following general, literature-based conditions may be relevant:
Cross-coupling on the 3‑iodobenzyl aryl iodide:
Stability considerations during any transformation:
Assay preparation (biological use; not a chemical reaction):
GHS/Regulatory (item-specific):
General laboratory precautions (good practice for halogenated nucleoside analogs; consult SDS for authoritative guidance):
Waste: Treat as halogenated organic waste. Do not discharge to drains.
Polarity/solvent class (general): A polar, multifunctional nucleoside analog with limited nonpolar character due to sugar and amide groups; dissolves best in strong H‑bond accepting, high-dielectric solvents.
Recommended solvents for stock solutions (literature guidance; not item-specific specs):
Practical tips:
When to choose alternatives:
Item-specific storage (from Product Data):
Container/packaging recommendations (best practice):
Reconstitution (general guidance; not item-specific specs):
Stability/use:
Compatibility:
Note: For definitive shelf life, purity, and assay data, refer to the lot-specific CoA/Spec Sheet.
A high-affinity small-molecule adenosine A3 receptor agonist analog supplied under Aladdin’s Moligand™ line.
Item-specific identifiers (from Product Data):
Structural class and features (general/literature description, not item-specific specs):
2D description in words (general): ribofuranose ring (five-membered) tethered via an N9 glycosidic bond to a 2‑chloro‑6‑substituted purine; the N6 substituent is a 3‑iodobenzyl moiety; the ribose 5′ is converted to an N‑methyluronamide.
Although primarily employed as a bioactive tool compound, limited synthetic manipulations are feasible for probe development and SAR studies (general literature guidance):
Reactive handles present:
Protection strategies:
Cautions:
Use as an analytical surrogate:
Not applicable to this product type. This is a small-molecule ligand, not an antibody or affinity reagent with a defined clone/isotype. For biological context, literature describes 2‑Cl‑IB‑MECA as a selective agonist of the adenosine A3 receptor (A3AR), but no item-specific target-binding data are provided here. Refer to CoA or primary literature for quantitative selectivity profiles.
La nostra guida alla selezione delle qualità copre purezza, stato dello stabilizzatore e idoneità all'applicazione per tutte le varianti del nostro catalogo.
Visualizza la guida alle qualità Moligand™ →